Benzinga's Top Initiations

Analysts at Stifel Nicolaus initiated coverage on

with a Buy rating. The target price for CoLucid Pharmaceuticals is set to $15. CoLucid Pharmaceuticals' shares closed at $8.68 on Friday. Analysts at JP Morgan initiated coverage on

with a Overweight rating. aTyr Pharma shares closed at $22.89 on Friday. Analysts at Cowen & Company initiated coverage on

with a Outperform rating. Adaptimmune Therapeutics' shares closed at $15.43 on Friday. Leerink Swann initiated coverage on

with a Outperform rating. The target price for Fate Therapeutics is set to $10. Fate Therapeutics' shares closed at $6.26 on Friday. Analysts at Jefferies initiated coverage on

with a Buy rating. The target price for Collegium Pharmaceutical is set to $20. Collegium Pharmaceutical's shares closed at $17.00 on Friday. Goldman Sachs initiated coverage on

with a Neutral rating. The target price for Tallgrass Energy is set to $35. Tallgrass Energy shares closed at $32.06 on Friday. Analysts at UBS initiated coverage on

with a Buy rating. The target price for Prothena Corporation is set to $58. Prothena Corporation shares closed at $39.44 on Friday. Bernstein initiated coverage on

with a Underperform rating. PetroChina shares closed at $118.49 on Friday. Analysts at Oppenheimer initiated coverage on

with a Outperform rating. The target price for Affimed is set to $14. Affimed shares closed at $10.43 on Friday. Morgan Stanley initiated coverage on

with a Overweight rating. The target price for Vanguard Natural is set to $20. Vanguard Natural shares closed at $15.88 on Friday.